Aptahem Full Year 2024 Earnings: kr0.69 loss per share (vs kr5.79 loss in FY 2023)

Aptahem (NGM:APTA) Full Year 2024 Results

Key Financial Results

• Net loss: kr8.57m (loss narrowed by 23% from FY 2023).
• kr0.69 loss per share (improved from kr5.79 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Pharmaceuticals contributing kr3.77m. The largest operating expense was General & Administrative costs, amounting to kr11.9m (96% of total expenses). Explore how APTA's revenue and expenses shape its earnings.

Aptahem shares are down 26% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Aptahem that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.